Maximilien Vermandel

Karazin is ahead of advanced technology!👏 Ahead of the start of the academic year, the Karazin BioMed laboratory has been equipped with the state-of-the-art Swiss bioprinter REGENHU R-GEN 200. This tool enables both students and experienced researchers to create implants and tissue equivalents —skin, corneas, bones, cartilage —that can be applied in transplantology, reconstructive surgery, regenerative medicine, traumatology, orthopedics, cardiac surgery, dentistry, as well as for testing new pharmaceuticals. From now on, Karazin scientists will also be able to work with live human cells, developing advanced applied scientific projects and providing high-quality training for new generations of specialists in medical bioengineering, biology, and medicine. The cutting-edge bioprinting technologies implemented in this device make it possible to create both ultra-thin coatings and three-dimensional structures from natural or synthetic polymers, biocompatible metals, ceramics, and even live human cells. They ensure highly precise reproduction of tissue structures based on medical imaging and computer modeling. “The launch of the bioprinter at Karazin University opens a new horizon for the development of medical bioengineering and the training of a new generation of specialists. This step demonstrates the potential of Ukrainian universities to be at the forefront of scientific research and to introduce advanced educational practices at the level of global standards,” noted Tetyana Kaganovska, Rector of V. N. Karazin Kharkiv National University. This is a powerful educational base for disciplines in biology, medicine, bioengineering, as well as a resource for the implementation of research projects of the National Research Foundation of Ukraine, the Ministry of Education and Science of Ukraine, and international grant programs. The introduction of this advanced equipment will foster the implementation of innovative technologies in pharmaceuticals and improve the quality of healthcare for Ukrainians. The robotic educational and production complex in bioprinting will serve as a platform for collaboration between the university, business, and industry in strategic areas of science, technology, and innovation development. The development and modernization of the university, as well as the purchase of this equipment, are carried out within the framework of the joint project of the Ministry of Education and Science of Ukraine and the World Bank “Improving Higher Education in Ukraine for Results” (UIHERP). Once again, Karazin University proves: the future of science is being created here and now, despite the war!

65

Highlighting integrins from extracellular vesicles as key players in the tumor microenvironment and metastasis: in this review article, Corina Ciobanasu at Alexandru Ioan Cuza University and Christophe Le Clainche at Institut de Biologie Intégrative de la Cellule - I2BC - discussed recent advances on the role of extracellular vesicle integrins in tumor initiation, proliferation, migration, and invasion. Integrins, a diverse family of cell adhesion molecules, were shown to regulate essential processes such as tumor differentiation, migration, growth, and neovascularization. Tumor-derived exosomes, a subtype of EVs, were found to be enriched in integrins reflective of their parent cells 🔗 https://lnkd.in/eurzD8wT These exosomal integrins promoted extracellular matrix remodeling, immune evasion, and vascular changes, and were strongly associated with tumor progression and organ-specific metastasis. Beyond their mechanistic role, exosomal integrins demonstrated potential as diagnostic and prognostic biomarkers due to their tissue-specific expression profiles. They also emerged as attractive therapeutic targets for disrupting tumor–stroma interactions and limiting metastatic dissemination. Overall, this study highlighted exosomal integrins as critical mediators of cancer biology and promising tools for advancing diagnosis and treatment. #extracellularvesicles #exosomes #integrins #cellmigration #Vesiculab

41

3 commentaires

PCR Perspectives: How to manage coronary artery disease in TAVI candidates 📺 and 🎧 https://lnkd.in/d-V_p_mm When facing TAVI candidates with CAD, the questions pile up: angiography for all? PCI before or after? In this discussion, Martine Gilard, antonio mangieri and Marco Barbanti share practical insights on timing and patient selection. #EuroPCR #TAVR #TAVI #interventionalcardiology

116

1 commentaire

In 2001, the average MS diagnosis took 4 years. Today, it’s 1 year — and with the updated 2024 McDonald Criteria, we’re aiming for even faster, more accurate answers. These changes include: - New diagnostic tools like optical coherence tomography (OCT) - Specialized criteria for children and people over 50 - The ability to diagnose MS without symptoms related to demyelination if other conditions are met - Increased diagnostic specificity using the central vein sign (CVS) and paramagnetic rim lesions (PRLs) Earlier diagnosis means earlier treatment, which can reduce relapses, slow disease progression, and improve quality of life. Learn more about what’s changed at https://lnkd.in/g4SFQQkQ

164

9 commentaires

💬"As a post-grad, we were already doing immediate implants without fully understanding the biology - and we learned from our mistakes." In this new Straumann® ProTalk episode, Prof. Dr. France Lambert reflects on the defining moments, projects, and people that shaped her journey into becoming one of Europe’s most recognized clinical educators and researchers. 🎧 Listen now on https://brnw.ch/21wWlb9 #Straumann #dentist #dentistry #implantology #dentalimplants #ProTalk #podcast #dentalpodcast #FranceLambert

58

We’re excited to share a first look at ongoing work combining advanced imaging and powerful biology on the Okomera platform. With the support of clinicians and researchers at Gustave Roussy, Lucile Mercier, PhD candidate at Okomera and Gustave Roussy, has been accessing fresh patient-derived luminal B breast cancer samples to explore tumor heterogeneity on organoids at unprecedented depth. In collaboration with Tomocube, Inc., and using their holotomography technology, we imaged organoids on Okomera chips after applying our newly developed on-chip immunostaining workflow. 🔬 CK8+ and CK5+ immunofluorescence staining reveals that organoids on the Okomera platform maintain the heterogeneous cancer cell composition from the patient tumour tissue. In addition, the emergence of CK8-/CK5- cells reflects the presence of stroma cells, an essential component of cancer microenvironment in these primary tumoroids. These results demonstrate how combining label-free 3D imaging with targeted staining on Okomera chips can open new doors in cancer modeling and drug discovery. ⏰ Stay tuned for our upcoming application note with Tomocube, Inc.—more details coming soon!

67

3 commentaires